← All FR Documents
Notice

National Institute on Drug Abuse; Notice of Meeting

In Plain English

What is this Federal Register notice?

This is a notice published in the Federal Register by Health and Human Services Department, National Institutes of Health. Notices communicate information, guidance, or policy interpretations but may not create new binding obligations.

Is this rule final?

This document is classified as a notice. It may or may not create enforceable regulatory obligations depending on its specific content.

Who does this apply to?

Consult the full text of this document for specific applicability provisions. The affected parties depend on the regulatory scope defined within.

When does it take effect?

No specific effective date is indicated. Check the full text for date provisions.

Why it matters: This notice communicates agency policy or guidance regarding applicable regulations.

Document Details

Document Number2025-15505
TypeNotice
PublishedAug 15, 2025
Effective Date-
RIN-
Docket ID-
Text FetchedYes

Agencies & CFR References

CFR References:
None

Linked CFR Parts

PartNameAgency
No linked CFR parts

Paired Documents

TypeProposedFinalMethodConf
No paired documents

External Links

📋 Extracted Requirements 0 found

No extractable regulatory requirements found in this document. This is common for documents that:

  • Incorporate requirements by reference (IBR) to external documents
  • Are procedural notices without substantive obligations
  • Contain only preamble/explanation without regulatory text

Full Document Text (564 words · ~3 min read)

Text Preserved
<NOTICE> DEPARTMENT OF HEALTH AND HUMAN SERVICES <SUBAGY>National Institutes of Health</SUBAGY> <SUBJECT>National Institute on Drug Abuse; Notice of Meeting</SUBJECT> Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse. This will be a hybrid meeting held in-person and virtually and will be open to the public, as indicated below, with attendance limited to space available. Individuals who plan to attend in-person or view the virtual meeting and need special assistance such as sign language interpretation or other reasonable accommodations, should notify Dr. Gillian Acca via email at <E T="03">gillian.acca@nih.gov</E> five days in advance of the meeting. The open session of the meeting can be accessed by registering at the following link: <E T="03">https://nida.nih.gov/about-nida/advisory-boards-groups/national-advisory-council-drug-abuse-nacda/national-advisory-council-agenda.</E> A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. <EXTRACT> <E T="03">Name of Committee:</E> National Advisory Council on Drug Abuse. <E T="03">Date:</E> September 9, 2025. <E T="03">Closed:</E> 10:30 a.m. to 11:45 a.m. <E T="03">Agenda:</E> To review and evaluate grant applications. <E T="03">Open:</E> 1:00 p.m. to 5:00 p.m. <E T="03">Agenda:</E> Presentations and other business of the Council. <E T="03">Meeting Format:</E> Hybrid Meeting. <E T="03">Place:</E> Neuroscience Center, Conference Room 1145/1155, National Institutes of Health, 6001 Executive Boulevard, Rockville, MD 20852 (In-Person and Virtual Meeting). <E T="03">Contact Person:</E> Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown Street, Bethesda, MD 20852, 301-443-6480, <E T="03">sweiss@nida.nih.gov</E> . <E T="03">Contact Person:</E> Gillian Acca, Ph.D., Health Scientist Administrator, Division of Extramural Research, Office of Extramural Policy, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09C70, 11601 Landsdown Street, Bethesda, MD 20852, 301-827-5863, <E T="03">gillian.acca@nih.gov</E> . Any interested person may file written comments with the committee by forwarding the statement to Dr. Gillian Acca via email at <E T="03">gillian.acca@nih.gov.</E> The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at <E T="03">https://www.nih.gov/about-nih/visitor-information/campus-access-security</E> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit. Information is also available on the Institute's/Center's home page: <E T="03">www.drugabuse.gov/NACDA/NACDAHome.html,</E> where an agenda and any additional information for the meeting will be posted when available. <FP>(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)</FP> </EXTRACT> <SIG> <DATED>Dated: August 12, 2025.</DATED> <NAME>Bruce A. George, </NAME> Program Analyst, Office of Federal Advisory Committee Policy. </SIG> <FRDOC>[FR Doc. 2025-15505 Filed 8-14-25; 8:45 am]</FRDOC> </NOTICE>
This text is preserved for citation and comparison. View the official version for the authoritative text.